Abstract
Recent research has contributed significantly to our understanding of the pathogenesis of acute disseminated intravascular coagulation. COVID-19 can be considered as a new underlying condition of disseminated intravascular coagulation. In this narrative review, current evidence is presented regarding biomarker differences between sepsis-induced and COVID-19-associated coagulopathies, supporting the importance of acquired antithrombin deficiency in the early differential diagnosis of septic coagulopathy and its potential impact on treatment with endogenous anticoagulants. Establishing new scoring systems for septic coagulopathy in combination with endogenous anticoagulant biomarker activities may allow for the identification of those in the heterogeneous population of sepsis patients who are more likely to benefit from targeted specific treatment interventions.
Keywords: COVID-19; antithrombin; biomarker; coagulopathy; disseminated intravascular coagulation; intervention; scoring; sepsis.
【저자키워드】 COVID-19, Biomarker, Intervention, Coagulopathy, Antithrombin, sepsis., Disseminated intravascular coagulation, Scoring, 【초록키워드】 Treatment, Pathogenesis, Sepsis, activity, Research, Coagulopathies, differential diagnosis, Anticoagulants, Anticoagulant, Evidence, Combination, scoring system, deficiency, specific treatment, heterogeneous population, recent, benefit, significantly, contributed, Establishing, sepsis patient, 【제목키워드】 lesson,